probenecid has been researched along with Community Acquired Infection in 1 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rao, PP | 1 |
| Mopkar, O | 1 |
| Desai, A | 1 |
1 trial available for probenecid and Community Acquired Infection
| Article | Year |
|---|---|
Comparative trial to evaluate the efficacy and tolerability of cefuroxime 250mg with probenecid 250mg with cefuroxime 500mg in the management of community acquired pneumonia, acute bronchitis and acute exacerbation of chronic bronchitis.
Topics: Acute Disease; Adult; Bronchitis; Cefuroxime; Cephalosporins; Community-Acquired Infections; Drug Th | 2000 |